Tricuspid Valve Incompetence Following Implantation of Ventricular Leads

Giselle A. Baquero, Jerry Luck, Gerald V. Naccarelli, Mario D. Gonzalez, Javier E. Banchs

Research output: Contribution to journalReview article

2 Citations (Scopus)

Abstract

Most cardiovascular implantable electronic devices (CIEDs) require a ventricular lead to be placed across the tricuspid valve. Tricuspid regurgitation (TR) is an understudied clinical complication of right ventricular lead implantation and its clinical significance is unknown. We review the incidence, predictors, and current management of TR as a complication of ventricular lead implantation. Emerging technologies, including leadless pacing devices and subcutaneous systems, offer the benefit of little or none tricuspid valve disruption.

Original languageEnglish (US)
Pages (from-to)150-157
Number of pages8
JournalCurrent Heart Failure Reports
Volume12
Issue number2
DOIs
StatePublished - Mar 4 2015

Fingerprint

Tricuspid Valve Insufficiency
Tricuspid Valve
Equipment and Supplies
Technology
Incidence
Lead

All Science Journal Classification (ASJC) codes

  • Emergency Medicine
  • Cardiology and Cardiovascular Medicine
  • Physiology (medical)

Cite this

Baquero, Giselle A. ; Luck, Jerry ; Naccarelli, Gerald V. ; Gonzalez, Mario D. ; Banchs, Javier E. / Tricuspid Valve Incompetence Following Implantation of Ventricular Leads. In: Current Heart Failure Reports. 2015 ; Vol. 12, No. 2. pp. 150-157.
@article{7f4ba825aad34e6e8efbe4ed456a1b2c,
title = "Tricuspid Valve Incompetence Following Implantation of Ventricular Leads",
abstract = "Most cardiovascular implantable electronic devices (CIEDs) require a ventricular lead to be placed across the tricuspid valve. Tricuspid regurgitation (TR) is an understudied clinical complication of right ventricular lead implantation and its clinical significance is unknown. We review the incidence, predictors, and current management of TR as a complication of ventricular lead implantation. Emerging technologies, including leadless pacing devices and subcutaneous systems, offer the benefit of little or none tricuspid valve disruption.",
author = "Baquero, {Giselle A.} and Jerry Luck and Naccarelli, {Gerald V.} and Gonzalez, {Mario D.} and Banchs, {Javier E.}",
year = "2015",
month = "3",
day = "4",
doi = "10.1007/s11897-014-0249-x",
language = "English (US)",
volume = "12",
pages = "150--157",
journal = "Current Heart Failure Reports",
issn = "1546-9530",
publisher = "Current Science, Inc.",
number = "2",

}

Tricuspid Valve Incompetence Following Implantation of Ventricular Leads. / Baquero, Giselle A.; Luck, Jerry; Naccarelli, Gerald V.; Gonzalez, Mario D.; Banchs, Javier E.

In: Current Heart Failure Reports, Vol. 12, No. 2, 04.03.2015, p. 150-157.

Research output: Contribution to journalReview article

TY - JOUR

T1 - Tricuspid Valve Incompetence Following Implantation of Ventricular Leads

AU - Baquero, Giselle A.

AU - Luck, Jerry

AU - Naccarelli, Gerald V.

AU - Gonzalez, Mario D.

AU - Banchs, Javier E.

PY - 2015/3/4

Y1 - 2015/3/4

N2 - Most cardiovascular implantable electronic devices (CIEDs) require a ventricular lead to be placed across the tricuspid valve. Tricuspid regurgitation (TR) is an understudied clinical complication of right ventricular lead implantation and its clinical significance is unknown. We review the incidence, predictors, and current management of TR as a complication of ventricular lead implantation. Emerging technologies, including leadless pacing devices and subcutaneous systems, offer the benefit of little or none tricuspid valve disruption.

AB - Most cardiovascular implantable electronic devices (CIEDs) require a ventricular lead to be placed across the tricuspid valve. Tricuspid regurgitation (TR) is an understudied clinical complication of right ventricular lead implantation and its clinical significance is unknown. We review the incidence, predictors, and current management of TR as a complication of ventricular lead implantation. Emerging technologies, including leadless pacing devices and subcutaneous systems, offer the benefit of little or none tricuspid valve disruption.

UR - http://www.scopus.com/inward/record.url?scp=84925483485&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84925483485&partnerID=8YFLogxK

U2 - 10.1007/s11897-014-0249-x

DO - 10.1007/s11897-014-0249-x

M3 - Review article

C2 - 25488281

AN - SCOPUS:84925483485

VL - 12

SP - 150

EP - 157

JO - Current Heart Failure Reports

JF - Current Heart Failure Reports

SN - 1546-9530

IS - 2

ER -